Polaris Group's Total Assets for the quarter that ended in Dec. 2025 was NT$8,167.93 Mil.
During the past 12 months, Polaris Group's average Total Assets Growth Rate was -9.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 43.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 38.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 14.60% per year.
During the past 12 years, Polaris Group's highest 3-Year average Total Assets Growth Rate was 58.60%. The lowest was -5.00%. And the median was 1.20%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Polaris Group's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Polaris Group Total Assets Related Terms
Polaris Group Total Assets Historical Data
* Premium members only.
The historical data trend for Polaris Group's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Polaris Group's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polaris Group (TPE:6550) has a Total Assets of NT$8,167.93 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Polaris Group and its competitors.
Is Polaris Group's Total Assets too high?
Polaris Group's current Total Assets is NT$8,167.93 Mil. Overall, Polaris Group has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Polaris Group's Total Assets compare to VRTX and REGN?
Polaris Group's Total Assets of NT$8,167.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Polaris Group and its competitors. Polaris Group's current Total Assets is NT$8,167.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaris Group stock overvalued right now?
Based on GuruFocus' analysis, Polaris Group (TPE:6550) is currently considered Possible Value Trap. The stock's GF Value™ is NT$55.35, compared to a current price of NT$13.55 — trading 75.5% below its estimated fair value. The current Total Assets is NT$8,167.93 Mil. Polaris Group's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Polaris Group (TPE:6550), the current Total Assets is NT$8,167.93 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polaris Group (TPE:6550) Overvalued in 2026?
Based on GuruFocus' analysis, Polaris Group stock appears to be undervalued.
The current stock price of NT$13.55 is trading 75.5% below its estimated GF Value™ of NT$55.35.
GuruFocus considers Polaris Group to be Possible Value Trap.
Key valuation signals for TPE:6550:
Total Assets: NT$8,167.93 Mil
GF Value™: NT$55.35 vs. price of NT$13.55 (75.5% below fair value)
No single metric tells the full story. See the TPE:6550 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
59GF Score
Get the complete analysis for TPE:6550
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6550 has been successfully added to your 
